The Latest Cardiac and Vascular News
Presented at Key Scientific Society Meeting – Commonly Used Pressure Measures for Volume Assessment Proven Not Equivalent to BVA Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart validating the benefits of the […]
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving […]
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart that was presented on April 2nd at the American College of Cardiology (ACC) 71st Scientific Sessions […]
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF) patients […]
Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD, MPA to its Board of Directors, effective January 18, 2022. Mr. DesRosiers is currently a Senior Principal at Valuate Healthcare Consultancy, a leading […]
Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable” by Lead Authors Oak Ridge, TN, Nov. 16, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the […]
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis guided management of acute decompensated heart failure (ADHF) utilizing […]
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center […]
NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major medical centers across the U.S. A leading academic medical center […]
NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data presented during the Heart Failure Society of America’s Annual Scientific Meeting focused on the use of Daxor’s BVA-100® blood […]
